Phase III FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer

Conditions:Cancer, Cancer, Pancreatic Cancer
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:August 2013
End Date:September 2021
Contact:Samantha Wong

Use our guide to learn which trials are right for you!

A Randomized Phase III Study Evaluating Modified FOLFIRINOX (mFFX) With or Without Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer

The goal of this study is to determine the safety and efficacy of a chemotherapy regimen
known as Modified FOLFIRINOX (mFFX) alone or with the addition of Stereotactic Body
Radiotherapy (SBRT). We hope to learn if this new treatment combination helps to control the
disease and improve survival for patients with locally advanced pancreatic cancer.

A Pancreatic Cancer Radiotherapy Study Group (PanCRS) Trial

Primary Objective:

To determine progression free survival for mFFX +/- SBRT.

Secondary Objectives:

- To determine metastasis free survival following mFFX chemotherapy alone or with SBRT.

- To determine the overall survival in pancreatic cancer patients treated with
chemotherapy +/- SBRT.

- To determine local progression-free survival in pancreatic cancer patients after
chemotherapy +/- SBRT.

- To evaluate acute (within 3 months of treatment) grade 2 or greater gastritis, fistula,
enteritis, or ulcer and any other grade 3-4 gastrointestinal toxicity within 3 months of

- To evaluate the utility of FDG-PET for treatment planning and estimation of progression
free survival.

- To identify new biomarkers in pancreatic cancer.

- To evaluate the quality of life of patients before and after either chemotherapy or
chemotherapy and SBRT.

Inclusion Criteria:

- Histologically confirmed adenocarcinoma of the pancreas.

- Induction mFolfirinox up to 4 cycles. Informed consent must be signed by the end of
the second cycle.

- Stable or better disease on re-staging scans.

- Determined unresectable by a pancreatic cancer surgeon or a multi-disciplinary or
gastrointestinal oncology Tumor Board.

- Typically, pancreatic tumors must be less than 8.0 cm in greatest axial dimension at
the time of treatment planning but final determination of eligibility will be based
upon satisfying the radiation normal tissue constraints as per protocol.

- ECOG 0, 1, or 2

- Patients must have acceptable organ and marrow function as defined below and within 30
days of eligibility confirmation:

- leukocytes (WBC) >=3,000/mL

- absolute neutrophil count (ANC)>=1,500mL

- platelets >=50,000/mL

- total bilirubin < or = 1.5 X institutional upper limit of normal

- AST(SGOT)/ALT(SGPT) < or =2.5 X institutional upper limit of normal

- creatinine within normal institutional limits

- Ability to understand and the willingness to sign an informed consent form.

- Life expectancy > 6 months.

Exclusion Criteria:

- Metastatic disease

- Patients who have had prior radiotherapy to the upper abdomen/liver.

- Patients who have received chemotherapy for pancreatic cancer, other than up to 4
cycles of mFolfirinox.

- Children are excluded because pancreatic tumors rarely occur in this age group.
Furthermore, treatment requires a great deal of patient cooperation including the
ability to lie still for several hours in an isolated room.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection (or infections requiring systemic antibiotic treatment), symptomatic
congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric
illness/social situations that would limit compliance with study requirements.

- Any concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder
cancer, or carcinoma in situ of the cervix. Patients with a previous malignancy
without evidence of disease for > 5 years will be allowed to enter the trial.

- Pregnant and breastfeeding women are excluded; as well as women of child-bearing
potential who are unwilling or unable to use an acceptable method of birth control
(hormonal or barrier method of birth control; abstinence) to avoid pregnancy for the
duration of the study. Male subjects must also agree to use effective contraception
for the same period as above. Should a woman become pregnant or suspect she is
pregnant while participating in this study, she should inform her treating physician

- Women who are not post-menopausal (as defined in Appendix III) and have a positive
urine or serum pregnancy test or refuse to take a pregnancy test
We found this trial at
Los Angeles, California 90095
(310) 825-4321
Phone: 559-624-3015
UCLA UCLA's primary purpose as a public research university is the creation, dissemination, preservation and...
Los Angeles, CA
Click here to add this to my saved trials
291 Campus Dr
Stanford, California 94305
(650) 725-3900
Principal Investigator: Daniel T Chang
Phone: 650-498-8495
Stanford University School of Medicine Vast in both its physical scale and its impact on...
Stanford, CA
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Phone: 843-792-3273
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Charleston, SC
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
(214) 645-3300
Phone: 214-645-7604
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
Dallas, TX
Click here to add this to my saved trials
Maywood, Illinois 60153
Phone: 708-216-2568
Maywood, IL
Click here to add this to my saved trials
1635 Divisadero Street
San Francisco, California 94143
San Francisco, CA
Click here to add this to my saved trials
Seattle, Washington 98104
Seattle, WA
Click here to add this to my saved trials
Vancouver, British Columbia
Phone: 604-877-6000
Click here to add this to my saved trials